Mylan, Edwards back NHK-Fintiv challenge

Mylan Pharmaceutical and Edwards Lifesciences have joined a petition urging the US Supreme Court to order the US Court of Appeals for the Federal Circuit to reconsider inter partes review (IPR) petitions that have been denied due to the NHK-Fintiv rule.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Edwards Lifesciences revives Fintiv challenge

14 March 2023 Medtech company wins reversal of earlier ruling | Door opens to mount a challenge of controversial rule | USPTO director‘s updated guidelines influence court’s reasoning.

Generics

Lawmakers urge USPTO to curb IPR denials under Fintiv

21 September 2021 Several US lawmakers have called upon the US Patent and Trademark Office to curb the increase in inter partes review denials to combat the “soaring cost” of prescription drugs.

Americas

Intel backs Mylan's anti-Fintiv SCOTUS stance

16 September 2021 Intel has backed Mylan's bid to convince the US Supreme Court to remove the controversial NHK-Fintiv rule, on the basis that it is “unlawful”.

More on this story

Americas

Edwards Lifesciences revives Fintiv challenge

14 March 2023 Medtech company wins reversal of earlier ruling | Door opens to mount a challenge of controversial rule | USPTO director‘s updated guidelines influence court’s reasoning.

Generics

Lawmakers urge USPTO to curb IPR denials under Fintiv

21 September 2021 Several US lawmakers have called upon the US Patent and Trademark Office to curb the increase in inter partes review denials to combat the “soaring cost” of prescription drugs.

Americas

Intel backs Mylan's anti-Fintiv SCOTUS stance

16 September 2021 Intel has backed Mylan's bid to convince the US Supreme Court to remove the controversial NHK-Fintiv rule, on the basis that it is “unlawful”.

More on this story

Americas

Edwards Lifesciences revives Fintiv challenge

14 March 2023 Medtech company wins reversal of earlier ruling | Door opens to mount a challenge of controversial rule | USPTO director‘s updated guidelines influence court’s reasoning.

Generics

Lawmakers urge USPTO to curb IPR denials under Fintiv

21 September 2021 Several US lawmakers have called upon the US Patent and Trademark Office to curb the increase in inter partes review denials to combat the “soaring cost” of prescription drugs.

Americas

Intel backs Mylan's anti-Fintiv SCOTUS stance

16 September 2021 Intel has backed Mylan's bid to convince the US Supreme Court to remove the controversial NHK-Fintiv rule, on the basis that it is “unlawful”.

More features

Trump’s march-in rights threat: Why pharma is rethinking collaborations

UK gets new IP minister following cabinet reshuffle

Barnes & Thornburg reveals five new IP leaders

Former PTAB judge joins Sterne Kessler

GSK escalates mRNA COVID-19 vaccine dispute

Smart ringleader: Could Ōura’s market dominance be under threat?

The flaw that landed Sanofi a win in the rare disease space

Roche resolves cancer test dispute with Stanford affiliated startup

Mylan, Edwards back NHK-Fintiv challenge

More on this story

Editor's picks

Editor's picks

More on this story

More on this story

More features